Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS NM Urinary Tumor Marker Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - New MexicoPolicy RPLAB038

    Urinary Tumor Markers for Bladder Cancer

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB038 alerts

    Get alerted when Policy RPLAB038 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines BCBSNM reimbursement stance for urinary tumor marker tests for bladder cancer diagnosis and surveillance, and identifies specific situations where tests are reimbursable or not; applies to providers submitting claims to Blue Cross Blue Shield - New Mexico.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyUrinary Tumor Markers for Bladder Cancer
    Policy CodePolicy RPLAB038
    Change TypeRevised reimbursement informationliterature and references updated
    Effective DateSep 4, 2026
    Last ReviewApr 29, 2025
    Next Review Date
    Key ActionSubmit accurate documentation and code claims using valid HIPAA-approved code sets; claims may be reviewed and additional documentation requested.
    SourceLink
    POLICY UPDATE CHANGES

    Reimbursement Information #1 and #2 were edited for clarity.

    References were revised during the most recent update.

    Several CPT/HCPCS codes (0012M, 0013M, 0363U, 0420U, 0452U, 0465U, 0549U) were removed in a prior update.

    3biomarker types reimbursable

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    clinical situations reimbursable
    4non-reimbursable tests/indications
    ~14procedure codes listed

    Coverage Criteria for Urinary Tumor Markers

    Reimbursement criteria

    Covered when ALL of the following criteria are met:

    Reimbursement applies only as specified below; other uses are not reimbursable.

    ONE of

    • ALL of the following

      • ONE of

        • Diagnostic exclusion of bladder cancer for individuals with atypical or equivocal cytology.
        • Monitoring of high-risk, non-muscle invasive bladder cancer.
    • Adjunct to cystoscopy or urinary cytology: fluorescence immunocytology (ImmunoCyt/uCyt) may be reimbursed when used for monitoring individuals with bladder cancer.
    Not reimbursable: urinary biomarkers (BTA, NMP22, FISH/UroVysion) and fluorescence immunocytology (ImmunoCyt/uCyt) are NOT reimbursable for the evaluation of hematuria, for screening asymptomatic individuals for bladder cancer, for diagnosing bladder cancer in symptomatic individuals, or for any other indications not specifically listed as reimbursable.
    Any other urinary tumor markers for bladder cancer not specifically mentioned (beyond BTA, NMP22, FISH/UroVysion, and ImmunoCyt/uCyt) are not reimbursable.

    Procedure Codes

    Listed procedure codesmixed
    86294IMMUNOASSAY TUMOR QUAL.
    86316IMMUNOASSAY TUMOR OTHER.
    86386NUCLEAR MATRIX PROTEIN 22.
    88120CYTP URNE 3-5 PROBES EA SPEC
    88121CYTP URINE 3-5 PROBES CMPTR.
    88346IMFLUOR 1ST 1ANTB STAIN PX.
    88350IMFLUOR EA ADDL 1ANTB STN PX.
    0365UONC BLDR 10 UR HRBR URTHL CA.
    0366UONC BLDR 10 PRB RECR BLDR CA.
    0367UONC BLDR 10 FLWG TRURL RESCJ
    Listed procedure codes (duplicate group record)mixed
    No codes listed

    Documentation, Claims, and Plan Eligibility

    Documentation Required

    Documentation and claim submission requirements

    Providers must submit accurate documentation of services performed and submit claims using valid HIPAA‑approved code sets (e.g., CPT, HCPCS, ICD-10) per industry coding guidelines; claims are subject to code edit protocols and may be reviewed and audited, and providers may be asked to submit additional documentation upon request.

    • Submit claims using valid code combinations from HIPAA‑approved code sets (CPT, HCPCS, ICD-10, etc.).
    • Code claims appropriately per industry standard coding guidelines and CCI/CM S rules.
    • Be prepared to provide additional documentation if requested during claim review or audit.
    Prior Authorization

    Verify plan‑specific eligibility before billing

    Not all lab management reimbursement requirements in this policy apply to every product; providers must review the member's individual Plan documents (Certificates, Benefit Booklets, Summary Plan Descriptions, provider contracts) to determine eligible coverage for services rendered.

    Key Definitions and Clinical Scenarios

    Adjunct to cystoscopy
    DefinitionUse of urinary biomarkers or immunocytology in addition to cystoscopy for diagnosis or monitoring as described in reimbursement criteria.
    Included testsBladder Tumor Antigen (BTA), Nuclear Matrix Protein 22 (NMP22), Fluorescence in situ hybridization (FISH/UroVysion), and Fluorescence immunocytology (ImmunoCyt/uCyt).
    Permitted adjunct usesDiagnostic exclusion of bladder cancer when cytology is atypical or equivocal; monitoring of high-risk non-muscle invasive bladder cancer.
    Not reimbursable when used instead of cystoscopyNot reimbursable for evaluation of hematuria, screening asymptomatic individuals, diagnosing symptomatic individuals, or other indications not explicitly listed as reimbursable.
    High-risk, non-muscle invasive bladder cancer (NMIBC)
    Definition
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyUrinary Tumor Markers for Bladder Cancer
    Policy CodePolicy RPLAB038
    Change TypeRevised reimbursement informationliterature and references updated
    Effective DateSep 4, 2026
    Last ReviewApr 29, 2025
    Next Review Date
    Key ActionSubmit accurate documentation and code claims using valid HIPAA-approved code sets; claims may be reviewed and additional documentation requested.
    SourceLink
    On This Page
    Coverage Criteria for Urinary Tumor MarkersProcedure CodesDocumentation, Claims, and Plan EligibilityKey Definitions and Clinical Scenarios
    • If a conflict exists between this reimbursement policy and a Plan document, the Plan document governs.
    • Provider contracts may supersede policy language where applicable—verify contract terms for coverage.
    • Review Plan documents to confirm whether specific urinary tumor marker tests are covered for the member prior to billing.
    Clinical scenario of non–muscle invasive bladder cancer with features that confer high risk for recurrence or progression.
    Reimbursable monitoringUrinary biomarkers (BTA, NMP22, FISH/UroVysion) may be reimbursed for monitoring individuals with high-risk, non-muscle invasive bladder cancer.
    Alternative adjunctFluorescence immunocytology (ImmunoCyt/uCyt) may be reimbursable as an adjunct to cystoscopy or urinary cytology in monitoring individuals with bladder cancer.
    LimitationsThese tests are not reimbursable for indications outside monitoring high-risk NMIBC (e.g., hematuria evaluation, screening, primary diagnosis).